[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100463947":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":30,"responsibleParty":49,"collaborators":20,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":20,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":20,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-N188","EXPERIMENTAL","Imaging cohort All study participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-N188 PET\u002FCT scan.",[13],"Drug: 18F-FDG",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","18F-FDG","All study participants will undergo one 18F-FDG PET\u002FCT scan.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Zhi Yang, Professor","CONTACT","010-88196495","pekyz@163.com",{"name":28,"role":24,"phone":25,"phoneExt":20,"email":29},"Hua Zhu, Professor","zhuhuabch@pku.edu.cn",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Beijing Cancer Hospital","RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":40,"coordinates":41},"Point",[42,43],116.39723,39.9075,{"lat":43,"lon":42},[46],{"name":47,"role":24,"phone":20,"phoneExt":20,"email":48},"Shunlian Zhou","zhoushunlian@163.com",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Hua Zhu","Professor","100463947","nectin-4-specific-lmw-pet-probe-imaging-in-urothelial-carcinoma-100463947",false,"NCT05321316","Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma","Inclusion Criteria:\n\n1. 18-75 years old, male or female;\n2. Heart function is normal;\n3. Normal heart function;\n4. Estimated survival ≥12 weeks;\n5. Good follow-up compliance;\n6. presence of at least one measurable target lesion according to RECIST1.1 criteria;\n7. Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before starting the test; Fertile men and women must agree to use effective contraception to prevent pregnancy during the study period and for 3 months after the test;\n8. Patients recommended by clinicians to undergo PET\u002FCT examination for tumor diagnostic staging;\n9. The subject patients could fully understand and voluntarily participate in the experiment, and signed the informed consent.\n\nExclusion Criteria:\n\n1. Serious abnormality of liver, kidney and blood;\n2. Pregnant patients;\n3. Pregnant and lactation women;\n\n3\\) unable to lie flat for half an hour; 4) Refuse to join the clinical investigator; 5) Suffering from claustrophobia or other mental diseases; 6) Other conditions that researchers deem unsuitable for participating in the experiment.",true,"ALL","18 Years","75 Years",{"count":64,"type":65},20,"ESTIMATED","INTERVENTIONAL",[68],"NA","To evaluate the ability of \\[68Ga\\]N188 to detect nectin-4 overexpression in patients with urothelial carcinoma, especially in patients with recurrent or advanced bladder cancer.",[71],"Urothelial Carcinoma","2026-03-02",{"date":74,"type":75},"2026-03-04","ACTUAL",{"date":77,"type":65},"2026-05-31",{"date":79,"type":65},"2026-12",{"name":5,"class":6},1]